Back to results
US 8,709,405 B2Granted
Cancer vaccines containing epitopes of oncofetal antigen
AssigneeSouth Alabama Medical Science Foundation
InventorsJoseph H. Coggin, Jr., James W. Rohrer, Adel L. Barsoum
Life of this patent
Estimating the term…
Abstract
Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated responses in mammalian cancer patients. They also have therapeutic uses in vitro.
Claims20
A method of autologous cancer therapy, comprising:
- culturing monocytes collected from a cancer patient in the presence of IL-4 and GM-CSF to allow differentiation of the monocytes into immature dendritic cells;
- culturing the dendritic cells in the presence of at least one oncofetal antigen (OFA) epitope that selectively stimulates T cytotoxic lymphocytes, and optionally at least one co-stimulant, to produce programmed dendritic cells, wherein the culturing is not conducted in the presence of an OFA epitope that specifically stimulates T suppressor cells;
- and
- administering the programmed dendritic cells to the cancer patient.
1 more element
A method of autologous cancer therapy, comprising:
- administering programmed autologous dendritic cells to a cancer patient, wherein the autologous dendritic cells were prepared by culturing monocytes collected from the cancer patient in the presence of IL-4 and GM-CSF to allow differentiation of the monocytes into immature dendritic cells;
- and culturing the dendritic cells in the presence of at least one oncofetal antigen (OFA) epitope that selectively stimulates T cytotoxic lymphocytes, and optionally at least one co-stimulant, to produce programmed dendritic cells, wherein the culturing was not conducted in the presence of an OFA epitope that specifically stimulates T suppressor cells.
Dependencies are inferred from the claim text.